Boehringer Ingelheim offers medications for the treatment of non-small cell lung cancer (NSCLC).
As well as a key focus on NSCLC, Boehringer Ingelheim is also building a strong pipeline in hematological cancers with a number of compounds currently being investigated in ongoing clinical trials in a number of indications including acute myeloid leukemia, myelodysplastic syndromes, chronic lymphocytic leukemia and non-Hodgkin lymphoma of B-cell origin.
Our comprehensive oncology pipeline extends beyond these two key areas encompassing more than ten clinical stage assets, being developed in various cancers and tumor types, including multiple NBEs and NCEs that are currently being investigated in studies involving more than 20,500 patients.
Scientists at our research and development center in Vienna, Austria, have extensive capabilities in both NCE and NBE discovery and the ambition to identify and translate the most promising scientific breakthroughs into clinical applications for patients across a wide range of cancers. Working in close collaboration with the international scientific community and a number of the world’s leading cancer centers, Boehringer Ingelheim is leading the way in the search for novel therapeutic concepts, biomarkers, drug candidates and treatment modalities.